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Glossary 
 
3’ss                3’ splice site 
5’ss                5’ splice site 
A   adenosine 
ATM   ataxia telangiectasia mutated 
bp   base pair 
BRCA1  breast cancer type 1 susceptibility protein 
C   cytidine 
cDNA   complementar DNA 
CFTR   cystic fibrosis transmembrane conductance regulator  
DMD   Duchenne muscular dystrophy 
DMEM  Dulbecco's modified Eagle medium 
DNA   deoxyribonucleic acid 
E. coli             Escherichia coli 
ESE   exonic splicing enhancer 
ESS   exonic splicing silencer 
G   guanosine 
Gal1P   galactose 1-phosphate 
GALE   UDP-galactose epimerase 
GALK   galactokinase 
GALM  galactose mutarotase 
GALT   galactose 1-phosphate uridylyltransferase 
HBB   hemogoblin beta 
hnRNP  heterogeneous nuclear ribonucleoprotein  
IEM   inborn error of metabolism 
ISE   intronic splicing enhancer 
ISS   intronic splicing silencer 
kb   kilo base pairs 
kDa   kilo Dalton 
LNA   locked nucleic acid 
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LB                  Luria-Bertani 
min                 minute(s)  
mRNA  messenger RNA 
mut   mutant 
NBCS   new born calf serum 
NMD   nonsense mediated decay 
PCR   polymerase chain reaction 
pre-mRNA  premature messenger RNA 
PTC   premature termination codon 
RBC  red blood cell 
RNA   ribonucleic acid 
RT-PCR  reverse transcription polymerase chain reaction 
sec                  second(s)  
SMaRT  spliceosome-mediated RNA trans-splicing 
snRNP  small nuclear ribonucleoprotein 
SR   serine/arginine-rich proteins 
T   thymidine 
U   uridine 
UDP   uridine diphosphate 
UMP   uridine monophosphate 
wt   wild-type 
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Abstract  
 
Galactose-1-phosphate uridylyltransferase (GALT) transfers a UMP group from UDP-
glucose to Gal1P in the second step of the Leloir pathway for galactose metabolism. 
Pathogenic mutations in the GALT gene cause deficient or absent activity of the enzyme and 
result in Classical Galactosemia. 
Mutational analysis of 27 Portuguese patients confirmed Q188R as the prevalent 
molecular defect (≈60%), and revealed the intronic variation c.820+13a>g (IVS8+13a>g) as 
the second most frequent mutation, accounting for 12.5% of the mutant alleles.  
In silico analysis revealed that the presence of the c.820+13a>g variation activates a 
cryptic splicing donor site and seems to create a strong ESE motif for the binding of the 
SRSF1 protein. 
 A minigene-based approach was used to analyze the effects of this presumptive pre-
mRNA splicing mutation. The pSPL3 vector containing either the genomic wild-type or 
mutant fragments was transfected into COS-7 and Hek293 cell lines. 24h after transfection, 
RNA was purified and amplified by RT-PCR. Direct sequencing analysis of the reaction 
products clearly showed that c.820+13a>g favors the next GT dinucleotide (c.820+14_15) to 
be used as a new 5’ splice donor site, leading to the inclusion of the first 13 nucleotides of 
intron 8 in the coding sequence, thus inducing a frameshift which generates a premature 
stop codon 17 amino acids downstream (p.D274fsX291).  
Additionally, in vivo studies demonstrated that, contrarily to the control individuals, a 
homozygous patient for c.820+13a>g mutation only presented alternative transcripts with the 
inclusion of the first 13 nucleotides of intron 8. 
Accordingly, c.820+13a>g may be considered indeed a disease-causing mutation, being 
the first intronic variation in the GALT gene whose molecular mechanism was elucidated.  
In order to revert this alternative splicing, an antisense oligonucleotide approach was 
attempted, using a LNA (locked nucleic acid) that was cotransfected with the minigenes in 
COS-7 and Hek293 cells; however, this preliminary experience was not effective, so new 
alternatives will be developed.   
 
Key-words: GALT, c.820+13a>g, alternative splicing, minigene assays, LNA. 
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Resumo  
 
A galactose-1-fosfato uridililtransferase (GALT) é a enzima responsável pelo segundo 
passo da via de Leloir, a principal via catabólica da galactose no organismo humano. A 
GALT transfere um grupo UMP da UDP-glucose para a galactose-1-fosfato (Gal1P), 
libertando glucose-1-fosfato (Glc1P) e formando UDP-galactose. Uma ausente ou deficiente 
actividade de GALT é causadora de Galactosémia Clássica (GC). A GC é uma doença 
metabólica rara que apresenta prevalência diversa de acordo com as diferentes populações, 
afecta cerca de 1 em cada 47 mil nados vivos nas populações caucasianas europeias e está 
associada a mutações no gene GALT. 
O gene GALT situa-se na região 13 do braço curto do cromossoma 9, cobre cerca de 4 
kb de DNA genómico e organiza-se em 11 exões. Este gene codifica uma proteína de 379 
aminoácidos com uma massa molecular de 43 kDa. A enzima activa é um homodímero com 
uma massa molecular total de 88 kDa. Até à data, foram já descritas mais de 200 variações 
no gene GALT. Embora a maioria sejam mutações pontuais do tipo missense, também 
foram detectadas mutações nonsense, alterações silenciosas, assim como deleções e 
mutações de splicing. Algumas destas variações são comuns, mas a maioria são raras e 
desconhece-se a sua importância funcional. As mais citadas são Q188R, K285N, S135L e 
N314D, sendo as duas primeiras as mais frequentes na população europeia.  
Estudos mutacionais em 27 doentes Portugueses confirmaram que a mutação Q188R é 
a prevalente (≈60%), e revelaram que a variação intrónica c.820+13a>g (IVS8+13a>g) é a 
segunda mais frequente, estando presente em cerca de 12,5% dos alelos mutados. 
Nas situações em que a conversão da Gal1P em Glc1P está comprometida, ocorre uma 
acumulação excessiva de galactose e de Gal1P, causando toxicidade no organismo. 
Actualmente, o único tratamento disponível consiste na restrição dietética de galactose, o 
qual diminui drasticamente a mortalidade neonatal por galactosémia. A longo prazo, apesar 
de salvar muitas vidas, esta terapia revela-se contudo insuficiente. Portanto, o 
desenvolvimento de novas terapias torna-se essencial. 
Os objectivos do presente estudo foram a elucidação do mecanismo patogénico 
subjacente à mutação c.820+13a>g, a confirmação do seu efeito in vivo e, por fim, a 
tentativa da sua correção através de terapia com oligonucleótidos antisense.  
Primeiramente, procedeu-se a um estudo in silico para prever a patogenicidade da 
mutação. O resultado revelou que a presença desta variação parece activar um sítio críptico 
(c.820+14_15) dador de splicing. Contudo, ao analisar a sequência mutada, este sítio 
críptico não foi reconhecido pelo programa NNSPLICE, mas apresentou uma pontuação de 
0,70 no programa NetGene2. Por outro lado, aquando da análise da sequência mutada, este 
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5’GT críptico foi reconhecido pelos dois programas mencionados, apresentando uma 
pontuação de 0,95 e 0,93, respectivamente. Estas pontuações revelaram-se superiores às 
obtidas pelo sítio de splicing natural, o qual foi pontuado, na sequência mutada,  com 
apenas 0,64 e 0,82 pelos programas NNSPLICE e NetGene2, respectivamente. 
Adicionalmente, na sequência mutada verificou-se o fortalecimento do motivo ESE (exonic 
splicing enhancer) para a ligação do factor de splicing SRSF1 (CCCAGGT, posições 9-15 do 
intrão 8). Com efeito, o ESE contendo o nucleótido mutado revelou uma pontuação de 
3,906278 enquanto que a presença do nucleótido normal conferia apenas a pontuação de 
1,986666, valor muito próximo do limiar do programa (1,956). 
Para a caracterização do mecanismo molecular subjacente a esta potencial mutação de 
splicing, recorreu-se à utilização da tecnologia dos minigenes. Para tal, os fragmentos 
genómicos de interesse, correspondentes à sequência génica normal e mutada do gene 
GALT, foram clonados no vector de splicing pSPL3 e designados pSPL3.wt e pSPL3.mut, 
respectivamente. De seguida, procedeu-se à sua transfeção em duas linhas celulares 
eucariotas, COS-7 e Hek293.  24 horas após transfeção, extraiu-se o RNA total celular que 
foi utilizado para amplificação por RT-PCR das sequências transcritas in vitro. A análise em 
gel de agarose do perfil transcricional  das duas linhas celulares demonstrou a existência de 
splicings alternativos, quer nas células transfectadas com o pSPL3.wt quer com o 
pSPL3.mut. A sequenciação de alguns destes fragmentos revelou que, tal como previsto in 
silico, a mutação favorece a utilização do 5’GT críptico que se localiza nos nucleótidos 
imediatamente a seguir, causando um splicing alternativo. Em ambas as linhas celulares 
transfectadas com pSPL3.mut, mas não nas transfectadas com pSPL3.wt, ocorre a inclusão 
dos primeiros 13 nucleótidos do intrão 8 nos transcritos. Esta inclusão na sequência 
codificante leva à mudança do quadro de leitura e à criação de um codão stop prematuro 18 
aminoácidos a jusante (D274fsX291).  
Paralelamente, estudos in vivo desmonstraram que, contrariamente ao esperado, os 
transcritos alternativos contendo um codão stop prematuro não sofreram NMD (nonsense 
mediated decay). De facto, a análise dos transcritos de um doente homozigótico para a 
mutação c.820+13a>g revelou, tal como nos indivíduos controlo, a presença de dois 
transcritos. Nos indivíduos controlo, o fragmento maior com 378pb corresponde a uma 
reação de splicing em que são utilizados os sítios naturais de splicing e, como tal, inclui o 
fim do exão 7, exão 8, exão 9 e início do exão 10; o fragmento menor com 294pb 
corresponde a um evento de splicing alternativo que leva à não inclusão do exão 9 na 
sequência final do mRNA. A análise do doente revelou o mesmo padrão de transcrição, 
diferindo os fragmentos observados na presença adicional dos 13 primeiros nucleótidos do 
intrão 8. Tendo em conta os resultados obtidos, foi possível concluir que o splicing 
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alternativo do exão 9 não é causado pela mutação c.820+13a>g, uma vez que também 
ocorre nos indivíduos controlo. 
Desta forma, confirmou-se que a mutação c.820+13a>g (IVS8+13a>g) é de facto 
causadora de doença, sendo a primeira variação intrónica no gene GALT cujo mecanismo 
molecular foi elucidado. 
De seguida, e com o intuito de reverter o splicing alternativo causado pela mutação, 
procedeu-se a uma tentativa da sua correção utilizando oligonucleótidos antisense. Para tal, 
e tendo em conta a proximidade da mutação ao sítio de splicing natural, selecionou-se a 
utilização de um LNA (locked nuclei acid). Após cotransfeção dos minigenes e do IVS8-LNA 
nas linhas celulares COS-7 e Hek293, isolou-se o RNA total celular e procedeu-se à 
respectiva amplificação por RT-PCR.  
Os padrões de splicing alternativo observados em ambas as linhas celulares foram 
semelhantes, quer em células não-tratadas, quer em células tratadas. Adicionalmente, a 
sequenciação de alguns dos fragmentos obtidos revelou a presença dos 13 primeiros 
nucleótidos do intrão 8 tanto nas células transfectadas com pSPL3.mut como nas células 
cotransfectadas com pSPL3.mut e IVS8-LNA. Assim, esta experiência preliminar revelou 
que o tratamento não foi eficaz na correção do splicing alternativo, realçando a necessidade 
de melhorar a presente metodologia ou de procurar outras alternativas terapêuticas. 
 
 
 
 
 
Palavras-chave: GALT, c.820+13a>g, splicing alternativo, minigene, LNA. 
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Introduction 
 
Health and disease depend on the delicate homeostasis of human organism. Gene 
expression is finely regulated to ensure that the correct complement of RNA and proteins is 
present in the right cell at the right time [1]. Any modification from transcription to protein 
function, may lead to phenotypic modifications, responsible for a disease state [2]. In addition 
to the exonic mutations that directly affect the protein, in the last two decades molecular 
genetics research has elucidated several mechanisms that alter gene function, such as 
epigenetic factors, distant regulatory elements and small interfering RNAs, as well as pre-
mRNA splicing defects. Indeed, this last type of alteration seems to play a role in almost all 
known diseases with a genetic etiology [3].  
Splicing involves precise removal of introns from pre-mRNA in a way exons are spliced 
together to form mature mRNAs with intact translation reading frames [2]. Exons are 
recognized through GT and AG intronic dinucleotides at the 5’ (donor) and 3’ (acceptor) 
exon-intron junctions, respectively, and also by the branch site (Figure 1) [2,4].  
 
Figure 1 - Classical splicing signals.  
Conserved motifs at or near the intron ends. The nearly invariant GU and AG dinucleotides at the intron ends, the 
polypyrimidine tract (Y)n preceding the 3′ AG, and the A residue that serves as a branchpoint are shown in a two-exon pre-
mRNA. The sequence motifs that surround these conserved nucleotides are shown below. For each sequence motif, the size of 
a nucleotide at a given position is proportional to the frequency of that nucleotide at that position in an alignment of conserved 
sequences from 1,683 human introns. Nucleotides that are part of the classical consensus motifs are shown in blue, except for 
the branch-point A, which is shown in orange. The vertical lines indicate the exon–intron boundaries. [5]. 
 
Splicing is then carried out by the interaction of these sequences with the spliceosome 
and further cut-and-paste (transesterification) reactions [2,4]. The spliceosome is made up of 
five small nuclear ribonucleoproteins (snRNPs) – U1, U2, U4/U6 and U5 snRNPs - and a 
large number of non-snRNPs [2,4]. Each snRNP is composed of a single uridine-rich small 
nuclear RNA and multiple proteins [4]. Despite being necessary, these classical splicing 
signals are by no means sufficient to define exon-intron boundaries [5]. In fact, pseudo-exons 
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are very common in introns and although they match the consensus splice-site signals as 
efficiently as the natural splice sites do, or sometimes even better, they are normally not 
included in mature mRNAs [5]. 
To increase the overall fidelity of the splicing reaction, additional sequences are present 
in exons and introns. These cis-acting sequence elements can act by increasing or 
decreasing recognition and are, respectively, named exonic or intronic splicing enhancers 
(ESE, ISE) or silencers (ESS, ISS) [2,6]. 
ESEs stimulate the use of splice sites through the specific binding of regulatory proteins, 
such as serine/arginine-rich (SR) proteins, which are thought to have a role in the initial steps 
of spliceosome assembly. Sequences that act as exonic splicing silencers (ESSs) have also 
been described, but are less well characterized than ESEs. In some instances, ESSs have 
been shown to bind negative regulators belonging to the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family [2, 5, 7] 
ESEs and ESSs appear to play a relevant role in the definition of constitutive exons and, 
additionally, these sequences participate in the regulation of alternative splicing [7]. 
A very common event in mammalian cells, which makes the already formidable task of 
correctly identifying splice sites even more complex, is alternative splicing [5], corresponding 
to the joining of different 5’ and 3’ splice sites (Figure 2) [4]. This process is responsible for 
much of the complexity of the proteome because it allows individual genes to express 
multiple mRNAs that encode proteins with diverse and even antagonistic functions [4,5]. 
 
 
Figure 2 - Modes of alternative splicing. 
Five common modes of alternative splicing. In each case, one alternative splicing path is indicated in green, the other path in 
red. In the last example, the alternative pathway corresponds to no splicing. In complex premRNAs, more than one of these 
modes of alternative splicing can apply to different regions of the transcript, and extra mRNA isoforms can be generated through 
the use of alternative promoters or polyadenylation sites. [5]. 
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Until recently, the effect of a mutation on gene expression was generally assumed 
according to its location. Exonic mutations were assumed to cause disease by affecting 
exclusively the coding potential: silent mutations were considered neutral; missense 
mutations were presumed to identify amino acid that are important for protein structure 
and/or function; and nonsense mutations were assumed to lead to expression of 
nonfunctional or deleterious truncated proteins [5]. These assumptions might be correct in 
some cases, but when they are not supported by characterization at the mRNA level, they 
could be misleading. In fact, many of the exonic mutations once thought to disrupt protein 
function actually disrupt splicing of the exon that contains the substitution [8]. Moreover, as 
research has progressed, it has become clear that almost any genomic variation, including 
translationally silent ones, even when found within intronic regions, should be considered as 
potential disease-causing mutation due to aberrant splicing [3]. Indeed, there is growing 
evidence that misclassification of mutations might commonly occur and that general extent of 
splicing mutations has been underestimated [5]. 
Most of the mutations that disrupt splicing are single nucleotide substitutions within the 
intronic or exonic segments of the classical splice sites and result in: i) complete exon 
skipping; ii) activation of a cryptic splice site; iii) intron retention; or iv) pseudo-exon inclusion. 
Also, mutations can disrupt splicing by introducing a new splice site within an exon or intron 
[4,9]. In most cases, use of unnatural splice sites or intron retention introduces premature 
termination codons (PTCs) into the mRNA, typically resulting in degradation by the 
nonsense-mediated decay (NMD) system [4]. Additionally, mutations may also affect the use 
of an alternative splice site leading to a shift of the ratio of natural protein isoforms [4]. 
Furthermore, some mutations may disrupt splicing by affecting a component of the splicing 
machinery, or by affecting a factor involved in splicing regulation [4].  
The recognition of the importance of splicing defects as main pathogenic mechanism 
underlying numerous genetic disorders assumes crucial importance in clinical practice [3]. 
Indeed, it is extremely important to interpret the clinical impact of genetic variations that may 
cause splicing defects.  
In order to investigate the pathogenicity of a splicing mutation, a minigene approach is 
usually used, relying on its first description in 1984. The minigenes contain a genomic 
segment from the gene of interest that includes the alternatively spliced region and flanking 
sequences, and represents a relatively fast approach for identifying splicing spoilers and the 
studying their underlying functional mechanisms [3,8]. 
Actually, it was soon realized that constitutive and regulated splicing reactions could be 
potential therapeutic targets and, accordingly, novel therapeutic strategies, directed toward 
correcting or circumventing splicing abnormalities, are now emerging [4,10]. Nowadays, 
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potential therapeutic approaches targeting splicing abnormalities include the use of small 
molecules, antisense oligonucleotides, bifunctional oligonucleotides, spliceosome-mediated 
RNA trans-splicing (SMaRT), isoform-specific RNA interference and modified U1 snRNPs 
[3,10]. 
One of the most successful approaches and a rapidly evolving field is the use of 
antisense oligonucleotides. These are thought to modulate splicing by steric hindrance of the 
recruitment of splicing factors to the targeted cis-elements, thus forcing the machinery to use 
the natural sites [3]. They can be used to inhibit the inclusion of unwanted exons and/or 
promote the production of a truncated but functional protein [3]. This type of therapeutic 
approach has already been tested in several genes involved in many common diseases, 
namely CFTR for cystic fibrosis, HBB for beta thalassemias, BRCA1 and ATM for cancer 
and, in particular, DMD for Duchenne muscular dystrophy to which a human clinical phase III 
trial has already been launched [3]. 
 
Galactosemia results from an impaired ability to metabolize galactose and galactose-
intolerant individuals were described in the medical literature as early as 1908 [11].  
In the human organism, most of the ingested galactose is rapidly metabolized to 
glucose-1-phosphate by the action of three consecutive enzymes: galactokinase (GALK) 
responsible for turning D-galactose into galactose-1-phosphate (Gal1P); galactose-1-
phosphate uridylyltransferase (GALT) which transfers a UMP group from UDP-glucose to 
Gal1P, thereby releasing glucose-1-phosphate and forming UDP-galactose; and UDP-
galactose epimerase (GALE) that catalyzes the interconversion of  UDP-glucose and UDP-
galactose [9,12]. These three enzymes constitute the main pathway of galactose catabolism, 
the Leloir pathway (Figure 3). Besides this metabolic pathway, a number of alternative 
pathways have been described [11,12]. 
 
Figure 3 - The Leloir pathway of galactose metabolism. 
 
Deficiency of any one of these enzymes in humans results in a form of galactosemia, 
being Classic Galactosemia the most common and clinically severe one. It is caused by 
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mutations in the GALT gene which profoundly impair the GALT enzyme, and affects about 
1/47,000 live-births [11,13]. Acute symptoms generally appear in the first weeks of life and 
include poor feeding and weight loss, vomiting, diarrhea, lethargy, and hypotonia; liver 
dysfunction is present in most cases, but bleeding tendencies, cataracts, and septicemia 
may also occur [11]. 
The human GALT gene (Figure 4) is located in chromosome 9p13, is arranged into 11 
exons spanning 4.37 kb of genomic sequence, and encodes a 379 amino acids protein with 
a molecular mass of 43 kDa. The active GALT enzyme is a homodimer with a total molecular 
mass of approximately 88 kDa [14].    
 
 
Figure 4 - The human GALT gene [15]. 
 
Like many other autosomal recessive metabolic disorders, Classical Galactosemia 
displays a great allelic heterogeneity with more than 200 variations described until now. Even 
though most of them are missense ones, silent, nonsense and noncoding changes have also 
been reported, as well as a large (~5kb) deletion, a number of small deletions and insertions 
and several splicing mutations (Figure 5) [11].  
 
Figure 5 – Classical Galactosemia mutation and variant distributions [16].  
 
The frequencies of specific GALT alleles appear to vary by population or racial group, 
likely reflecting founder effects or other genetic forces [11]. A few mutations are frequent, but 
most are rare. The most frequently cited are Q188R, K285N, S135L and N314D [17] being 
Q188R and K285N the two most prevalent mutations in European populations with 
frequencies depending on the studied population [18]. The S135L mutation is found almost 
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exclusively in the Afro-Americans being the most frequently reported mutation in this 
population [12]. 
Mutational analysis of 27 Portuguese patients confirmed the Q188R as the prevalent 
molecular defect (≈60%), and surprisingly revealed an intronic variation, c.820+13a>g 
(IVS8+13a>g), as the second most frequent variation, accounting for 12.5% of the mutant 
alleles. c.820+13a>g is believed to affect pre-mRNA splicing, and therefore to be a disease-
causing mutation since it has never been identified in controls and was only found in 
Portuguese patients either in homozygous or compound heterozygous state. It is noteworthy 
that this change has also been found in a Spanish family from Galicia which is in the 
neighborhood of Portugal [19].  
A diagnosis of GALT deficiency may arise from the investigation of acute illness or may 
be made presymptomatically following an abnormal newborn screening result [11], which 
utilizes a small amount of blood obtained from heel prick to assay GALT activity and quantify 
Gal1P and galactose concentrations in total red blood cells (RBC) [20]. When GALT activity 
is deficient, Gal1P and galactose accumulate and Gal1P competes with UTP-dependent 
glucose-1-P pyrophosphorylase to reduce UDP-glucose production [20]. 
Traditional treatment consists in a severe restriction of dietary galactose, which is life-
saving, but clearly insufficient since long-term follow-up of patients has shown that they 
develop symptoms such as retarded mental development, verbal dyspraxia, motor 
abnormalities and hypergonadotrophic hypogonadism in women [12]. Endogenous 
production of galactose, which may be up to 1 gram per day in adult patients, has been 
suggested to be a major cause of these late complications [21]. Accordingly, new therapeutic 
approaches are urging.  
The objectives of the present project are to develop the adequate methodology allowing 
the elucidation of the pathogenic mechanism underlying the c.820+13a>g mutation, which 
potentially affects the natural splicing reaction, to confirm its effect in patients carrying the 
mutations and, finally, to eventually correct it. 
We hope that this study will expand the knowledge on the molecular mechanisms 
underlying Classical Galactosemia pathogenesis and provide another step into the 
development of an alternative and efficient therapeutic approach. 
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Materials and methods 
 
In Silico Analyses of Splice Site Strength and ESE and ESS Motifs 
The strength of authentic and cryptic splice sites was assessed by web-based tools: 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) [20,21] for human sequences, and 
NNSPLICE 0.9 (http://www.fruitfly.org/seq_tools/splice.html) [22] with default settings for 
human or other organism, no reverse strand included and a minimum score for both 5’ and 3’ 
splice sites of 0.4. Both programs predict the presence of donor or acceptor sites by 
attributing a score to the possible splice sites. The scanned wild-type and mutant GALT gene 
sequences were 399bp long and included the last portion of intron 7, whole exon 8, intron 8, 
exon 9, and the first portion of intron 9 (Mutant Sequence in Supplementary data). Scores 
were then analysed and compared. 
Predictive programs RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) [23] and 
ESEfinder 3.0 (http://rulai.cshl.edu/tools/ESE/) [24,25] were used for ESE motifs, and FASS-
ESS Web server (http://genes.mit.edu/fas-ess/) [26], using both set of hexamers (FAS-hex2 
and FAS-hex3), for ESS motifs. RESCUE-ESE identifies hexamers whose sequences are 
possible binding sites of several known RNA binding factors, and predicts whether a 
mutation disrupts any of these elements. ESEfinder 3.0 identifies ESE responsive to the 
human SR proteins: SRSF1, SRSF2, SRSF5 and SRSF6, formerly known as SF2/ASF, 
SC35, SRp40 and SRp55, respectively, and predicts whether a mutation disrupts or 
enhances the binding of any of these proteins. The same 399bp wild-type and mutant GALT 
gene fragments were analysed with default settings for human sequences and default 
thresholds, and the scores compared.  
 
Cloning of the human GALT gene and minigene construction   
Genomic fragments encompassing the region of the GALT gene containing the 
c.820+13a>g variation were isolated from a control individual and from a Portuguese patient 
heterozygous for this mutation. This fragment, including the last portion of intron 7, whole 
exon 8, intron, exon 9, and the first portion of intron 9, was PCR amplified using the Taq DNA 
Polymerase (Invitrogen Corporation, Carlsbad, CA, USA) and primers 8+9F and 8+9R (Table 
1). The cycling conditions were: 5 min at 94ºC, 1 min at 58ºC, 2 min at 72ºC, 30 cycles of 40 
sec at 94ºC, 40 sec at 58ºC, 90 sec at 72ºC, followed by a final extension during 5 min at 
72ºC. 
The fragments were cloned into pCR-2.1TOPO vector (Invitrogen), according to 
manufacturer’s instructions. The recombinant plasmids were further transformed into One 
Shot TOP10 Chemically Competent E. coli cells (Invitrogen), according to manufacturer’s 
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instructions and the positive clones were cultured overnight (37ºC, 150 rpm) in 10mL of LB 
medium containing kanamycin (50µg/ml). Plasmids were isolated using Ron's Plasmid Mini 
Kit (Bioron Gmbh, Ludwigshafen, Germany) and their concentration and purity was 
determined in a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). To confirm the integrity of the desired fragments, direct sequence 
analysis was then performed using the ABI Prism BigDye Terminator Cycle Sequencing 
Ready Reaction Kits, in an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA). 
Recombinant plasmids were then digested with EcoRI (NZYTech, Lisbon, Portugal), the 
restriction products were separated by 2% agarose gel electrophoresis and further purified 
using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The pSPL3 exon-trapping 
vector (kindly supplied by Bélen Pérez, Madrid, Spain) was digested with EcoRI and the 
linearization was confirmed by electrophoretic analysis. Then it was purified using the 
QIAquick Gel Extraction Kit (Qiagen) and dephosphorylated with Alkaline Phosphatase 
(NZYTech). 
The ligation reaction of the desired fragments with the vector was performed using 
Speedy Ligase (NZYTech) and the recombinant plasmids were transformed into One Shot 
TOP10 Chemically Competent E. coli cells. A few clones were cultured overnight (37ºC, 150 
rpm) in 10mL of LB medium containing ampicilin (50µg/ml). After isolation, concentration and 
purity were determined as previously described. Direct sequence analysis was performed in 
order to confirm the presence of the desired fragments, wild-type and mutant sequences, into 
the pSPL3 vector.  
  
In vitro splicing analysis  
Minigene constructs containing wild-type and mutant sequences, pSPL3.wt and 
pSPL3.mut respectively, as well as the empty vector, pSPL3, were transfected into 
appropriate eukaryotic cell lines, namely COS-7 and Hek293. Cells were cultured in 6-well 
plates with DMEM medium containing 10% NBCS, 1% penicillin/streptomycin, and 2mM 
glutamine (all products from Invitrogen) and further transfected in duplicates using 1µg of 
plasmid DNA and GeneJuice™ (Novagen, Merck KGaA, Darmstadt, Germany) according to 
manufacturer’s instructions. After 24 hours, total RNA was extracted using the Trizol reagent 
(Invitrogen) and the first-strand cDNA was synthesized using the NZY First-Strand cDNA 
Synthesis Kit (NZYTech). PCR amplification was carried out using the Taq DNA Polymerase 
(Invitrogen) and primers SD6 and SA2 (Table 1), which hybridize with the vector sequence 
and thus prevent the amplification of the endogenous GALT transcripts. The cycling 
conditions were the following: 30 min at 50ºC, 15 min at 95ºC, 40 cycles of 30 sec at 95ºC, 
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30 sec at 55ºC, 1 min at 72ºC, followed by 10 min at 72ºC. PCR products were separated by 
2% agarose gel electrophoresis, extracted and purified using the Isolate PCR and Gel Kit 
(Bioline, UK) and directly sequenced to characterize the effect of the mutation. 
 
In vivo splicing analysis  
Total cellular RNA was isolated from lymphocytes of a control individual and a patient 
homozygous for the IVS8+13a>g mutation using the Trizol reagent (Invitrogen). First-strand 
cDNA was synthesized using the NZY First-Strand cDNA Synthesis Kit (NZYTech) and then 
PCR amplified using the Taq DNA Polymerase (Invitrogen) and CF and CR primers (Table 1) 
with the following cycling conditions: 5 min at 94ºC, 1 min at 60ºC, 2 min at 72ºC, 30 cycles 
of 40 sec at 94ºC, 40 sec at 60ºC, 90 sec at 72ºC, followed by 7 min at 72ºC. Amplification 
products, encompassing the mutation region, were visualized by agarose gel 
electrophoresis. After separation by 2% NuSieve GTG agarose gel electrophoresis, PCR 
products were purified as previously described, and further analysed by direct sequencing.  
 
Correction of alternative splicing  
Cell culture and minigene transfection followed the same protocol previously referred. 
Five hours afterward, antisense oligonucleotide IVS8-LNA (5’CCAGGATCCTACCTG3’) 
(Exiqon, Vedbaek, Denmark) was transfected using the INTERFERin reagent (Polyplus 
transfection, Illkirch, France), according to the manufacturer’s instructions, and to final 
concentrations of 0, 15, 30 and 75nM. 24 hours later, conventional RT-PCR for splicing 
analysis was performed as described above.  
 
Table 1 - Nucleotide sequences of primers used in this study.  
Primer Sequence 
8+9F 5’CACCTTGATGACTTCCTATCCA3’ 
8+9R 5’GAAATGGTGTTGGGGCTAAA3’ 
SD6 5’TCTGAGTCACCTGGACAACC3’ 
SA2 5’GCTCACAAATACCACTGAGAT3’ 
CF 5’GTGAGGAGCGATCTCA3’ 
CR 5’TCATTACTACCCTCCGCTCC3’ 
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Results 
 
The intronic mutation c.820+13a>g (IVS8+13a>g) promotes the activation of a cryptic 
5’ splicing donor site.   
In order to predict if the c.820+13a>g mutation directly affects the pre-mRNA splicing of 
the GALT gene or if alternatively is just a marker linked to another causative mutation, and to 
understand the possible mechanism underlying it, wild-type and mutant sequences of the 
previously referred 399bp fragment (for details see Materials and Methods) were scanned by 
two different programs for splice site prediction and the relevant scores were compared 
(Table 2).  
 
Table 2 - In silico analyses for splice site prediction in wild-type and mutant GALT fragments. 
 
Position in the 
GALT fragment 
 NNSPLICE NetGene2 
 wt mut wt mut 
 
5’GT 
170_171 Intron 8  0.64 0.64 0.88 0.82 
183_184 Intron 8  - 0.95 0.70 0.93 
768_769 Intron 9  0.86 0.86 0.00 0.00 
3’AG 
35_36 Intron 7 0.98 0.98 0.00 0.00 
181_182 Intron 8  - 0.51 - - 
271_272 Intron 8  0.45 0.45 0.55 0.55 
 
Although both programs calculate scores according to different algorithms, analyses 
gave similar results. Authentic 5’GT of intron 8 presented the same or similar scores in both 
wild-type and mutant sequences in each program. Even thought scores were higher in 
NetGene2 (0.88 for wild-type and 0.82 for mutant sequence), in NNSPLICE the score was 
0.64 in both sequences. Being so, these results are indicative that this is not a weak splicing 
donor site.  
Both programs also predicted a new GT donor site (c.820+14_15) in the presence of the 
mutation. In the NNSPLICE program it was only recognized in the mutant sequence, in which 
it presented a score of 0.95, whereas in the NetGene2 program it was scored 0.70 and 0.93 
in the wild-type and mutant sequences, respectively. This cryptic splice site is located 
immediately after the mutation (c.820+14_15) and, in the presence of the mutation, both 
programs conferred it a higher strength comparatively to the natural 5’ splice site. These 
results suggested that in vivo c.820+14_15 splice site probably prevails over the canonical 5’ 
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splice site, being used by the spliceosome machinery and leading to the inclusion of the first 
13 nucleotides of intron 8 in the coding sequence. 
The authentic 5’GT from intron 9 showed the same scores (0.86) in wild-type and 
mutant sequences in the NNSPLICE program; however, it scored 0.00 in the NetGene2 
program.  
When analyzing the authentic 3’ splice acceptor sites, we noticed that the one in intron 7 
showed high scores (0.98) in the NNSPLICE program, while in the NetGene2 program it was 
scored 0.00. The acceptor site in intron 8 showed very low scores (0.45 and 0.55) in both 
programs, revealing its intrinsic weakness. The NNSPLICE program revealed that the 
mutation seams to create a new splice acceptor site in intron 8, immediately upstream the 
activated cryptic donor site, which however showed no significant strength (0.51).  
 
The intronic mutation c.820+13a>g (IVS8+13a>g) enhances the binding score of the SR 
protein SRSF1.  
Splicing mechanism is also dependent on the presence of splicing enhancers and 
silencers and, for that reason, we scanned the wild-type and mutant sequences for the 
presence of ESEs and ESSs using different web-based programs (for details see Materials 
and Methods).  
Concerning the presence of ESE sequences, the ESEfinder 3.0 program scored the 
same or very similar values for three of the SR proteins analysed (SRSF2, SRSF5, SRSF6) 
in both wild-type and mutant sequences. However, when analyzing the results for the SRSF1 
protein, we could notice that its binding score increased from being 1.986666 in the wild-type 
sequence, which is close to the lower threshold (1.956), to having a much higher score of 
3.906278 in the mutant sequence (CCCAGGT, positions 9-15 of intron 8, mutation position 
underlined). Nevertheless, the RESCUE-ESE program identified in the same region a 
binding sequence (CAAGTA, positions 11-16 of intron 8) for the same SRSF1 protein in the 
wild-type sequence, but not in the mutant one. 
As candidate ESSs, the FASS-ESS program predicts a binding sequence corresponding 
to the same positions in the wild-type (AGTAGG, positions 13-18 of intron 8) and mutant 
(GGTAGG, positions 13-18 of intron 8) sequences. In addition, another hexamer is predicted 
when analyzing the mutant sequence (AGGTAG, positions 12-17 of intron 8), overlapping the 
previous one.   
Altogether, these data suggested that c.820+13a>g mutation favors the next cryptic GT 
dinucleotide (c.820+14_15) to be used as a new splicing donor site, and simultaneously 
create in that region (CCCAGGT, positions 9-15 of intron 8) a stronger ESE motif, which 
potentially enhances the binding of the splicing factor SRSF1.  
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The intronic mutation c.820+13a>g (IVS8+13a>g) is sufficient to cause aberrant 
splicing of the GALT transcript. 
Having into account the in silico results, and in order to investigate if the c.820+13a>g 
mutation directly causes activation of the intronic cryptic GT, we cloned the previously 
referred 399bp fragment containing the wild-type and mutant regions of the GALT gene into 
the pSPL3 exon-trapping vector. Minigene constructs, pSPL3.wt and pSPL3.mut, differ 
exclusively in the 13th nucleotide of the intron 8, as shown in Figure 6. Eukaryotic COS-7 and 
Hek293 cell lines were transiently transfected with each construct, splicing products were 
analysed by RT-PCR in an agarose gel electrophoresis (Figures 7 and 8), and further 
analysed by direct sequencing. Both cell lines revealed the presence of alternative splicing 
events with either pSPL3.wt or pSPL3.mut.  
 
 
Figure 6 – Minigene constructions. 
A 399bp fragment of the GALT gene, containing either the wild-type (A) or the mutant (B) sequence, was cloned                        
in the EcoRI site of the pSPL3 vector. 
 
 
Figure 7 - Transcriptional profile of COS-7 cell line after transfection.  
pSPL3.wt, (wild-type minigene), pSPL3.mut (mutant minigene), pSPL3 (empty vector).  
M - Molecular marker Hypperladder II (Bioline). 
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Figure 8 - Transcriptional profile of Hek293 cell line after transfection.  
pSPL3.wt, (wild-type minigene), pSPL3.mut (mutant minigene), pSPL3 (empty vector).  
M – Molecular marker pBR322xMspI (New England Biolabs). 
 
 
A schematic interpretation of the most prominent transcripts is shown in Figures 9, 10 
and 11 and, as we can see, the different fragments correspond to the usage of different 
splicing donor and acceptor sites.  
COS-7 cells transfected with pSPL3.wt, pSPL3.mut and empty pSPL3 all presented a 
263bp fragment, corresponding to vector sequence only; on the other hand, in Hek293 cells, 
this same fragment was present when transfected with pSPL3.wt and empty pSPL3, but was 
not detected when transfected with pSPL3.mut. As depicted in Figure 9, this fragment arises 
from a single splicing event, in which the pSPL3 natural acceptor and donor splice sites are 
used. This fragment was expected, since the insertion of the fragments in pSPL3 had no 
evident effect in the vector splice sites strengths. In silico analysis with NNSPLICE program 
revealed a score of 0.94 for 5’GT with and without the cloned fragments, and 3’AG scored 
0.64 in the empty vector and 0.67 in both constructs. Moreover, this analysis revealed also a 
cryptic 5’GT donor site in the pSPL3 sequence which scores 0.81 when fragments are 
present and 0.94 when only the empty pSPL3 is analysed. 
 
 
Figure 9 - Schematic interpretation of the 263bp minigene fragment. 
Splicing mutations: making sense with antisense therapy 
 
 
Sílvia Pires Lourenço, FCUL 2012                                                                                                        14 
 
The transcriptional profile of COS-7 cells transfected with the pSPL3.wt is rather 
complex, presenting several fragments: a stronger one with 583bp, followed by 649, 396, 
752 and 480bp fragments. The 396bp fragment included pSPL3 and exon 8 sequences 
(Figure 10.A).  
 
 
Figure 10 - Schematic interpretation of the wild-type minigene transcriptional fragments. 
 
Indeed, this splicing event used 5’GT of pSPL3 with 3’AG of intron 7, and 5’GT of intron 
8 with 3’AG of pSPL3 (Figure 10.A). The 583bp fragment included both exon 8, intron 8 and 
exon 9 (Figure 10.B), in which splicing event used 5’GT of pSPL3 with 3’AG of intron 7, and 
5’GT of intron 9 with 3’AG of pSPL3. In this case, occurred retention of intron 8.  Analogously 
to the previous fragment, the 752bp fragment, included exon 8, intron 8 and exon 9; 
however, splicing event differs from the former, since 5’GT of intron 9 was not used, and 
instead cryptic 5’GT of pSPL3 was used preferentially, leading to the inclusion of an 
additional 169bp fragment (Figure 10.C). Two additional bands, putatively corresponding to 
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fragments with 480bp and 649bp, were not sequenced but most probably correspond to 
well-defined splicing events. In the first case, to the usage of all the canonical splice sites 
leading to a fragment containing the vector sequences plus exons 8 and 9. In the second 
case, the usage of all the canonical splice sites, except the 5’GT of intron 9 that was 
replaced by the cryptic GT of pSPL3 vector, led to a fragment containing vector sequences 
plus exons 8 and 9 and the additional 169 nucleotides of the vector sequence (Figure 7). 
The transcription process in COS-7 cells transfected with pSPL3.mut presented a 
simpler profile with only four bands of similar intensities (Figure 7).  
 
 
 
Figure 11 - Schematic interpretation of the mutant minigene transcriptional fragments. 
 
The smallest and more abounding fragment, with 409bp, corresponded to a splicing 
event using the 5’GT of pSPL3 with 3’AG of intron 7, and the cryptic 5’GT (c.820+14_15) of 
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intron 8 with 3’AG of pSPL3 (Figure 11.A). The 493bp fragment includes both exons 8 and 9 
as well as the first 13 nucleotides of intron 8 (Figure 11.B). The 662bp fragment results from 
the utilization of the previous splice sites, except the canonical 5’GT of intron 9 which was 
replaced by the cryptic one in the vector sequence, inducing the inclusion of the additional 
169bp (Figure 11.C). Finally, a fourth band putatively with 583bp was visualized, but not 
sequenced, and it most probably corresponds to a splice site selection causing the inclusion 
in the transcript of exon 8, whole intron 8 and exon 9. 
The splicing of wild-type and mutant minigenes in Hek293 cells revealed a similar but 
cleaner transcriptional profile (Figure 8). The wild-type minigene, besides the 263bp fragment 
containing only vector sequences, only revealed three bands (396, 583 and 752bp) similar to 
the ones detected in COS-7 cells; the 480 and 649bp fragments were present at a residual 
level. On the other hand, the transcription profile of the mutant minigene, when compared to 
the COS-7 cells one, revealed an extremely significant band with 409bp and three additional 
faint bands with 493, 583 and 662bp. 
Results obtained with both constructs in two different eukaryotic cell lines (one from 
monkey and the other from human) showed that c.820+13a>g mutation per se activates a 
strong cryptic 5’ splicing donor site, which leads to the inclusion of the first 13 nucleotides of 
intron 8 in the resulting mature mRNA, being responsible for inducing aberrant splicing of the 
GALT transcript. 
 
In order to confirm in vivo the pathogenic mechanism of c.820+13a>g mutation, total 
RNA was isolated from a control individual and from a patient homozygous for the mutation. 
RT-PCR of the transcript region of interest was performed and the amplified cDNA products 
visualized by agarose gel electrophoresis (Figure 12). 
The results revealed that both control and patient presented two fragments. Direct 
sequence analysis of the larger control band, 378bp long, revealed a splicing reaction using 
the canonical splice sites and thus including the end of exon 7, entire exons 8 and 9 and the 
beginning of exon 10, as expected (Figures 12). However, the smaller 294bp fragment 
revealed to correspond to an alternative splicing event leading to the skipping of exon 9. 
Surprisingly, the alternative transcript was more abundant than the wild-type one. When 
analyzing the patient’s fragments, we confirmed that they only differ from control individuals’ 
ones by the additional 13bp corresponding to the first nucleotides of intron 8 (Figure 12 and 
13). Nevertheless, the alternative transcript corresponding to exon 9 skipping was much less 
abundant.  
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Figure 12 - Agarose gel electrophoresis of the GALT cDNA fragments encompassing the desired sequence.  
C: control, P: patient, M: molecular weight marker Hypperladder II (Bioline),  
 
These results revealed that the alternative splicing which leads to the skipping of exon 9 
is not caused by the c.820+13a>g mutation since it also occurs in homozygous wild-type 
individuals. Besides, we could confirm the in vitro results, namely that the c.820+13a>g 
(IVS8+13a>g) mutation activates in vivo a cryptic 5’ splicing donor site in intron 8, leading to 
a splicing defect, and that it is in fact a disease-causing mutation. 
 
 
Figure 13 - Partial sequences of the patient’s RT-PCR bands corresponding to canonical 3’ss splicing (A) and to 
alternative splicing involving skipping of exon 9 (B). In both cases the first 13 nucleotides of intron 8 are present. 
A 
B 
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The LNA approach was not effective in the correction of the splicing defect caused by 
c.820+13a>g (IVS8+13a>g) mutation. 
The correction of the splicing defect was attempted using a locked nucleic acid (LNA) 
approach. After transfection of COS-7 and Hek293 cell lines with the wild-type (control) and 
mutant minigenes, and subsequent transfection with the IVS8-LNA, total RNA was isolated 
and RT-PCR analysis was performed.  
The alternative splicing patterns observed in both cell lines were similar when comparing 
the untreated versus treated cells (Figure 12). Sequence analysis of some of the fragments 
revealed the presence of the first 13 nucleotides of intron 8, not only in the cells transfected 
with the mutant minigene, but also in the cells cotransfected with the mutant minigene and 
the IVS8-LNA. The cells transfected with the wild-type minigene were used as negative 
control and we could confirm that the treatment with LNA had no effect on their splicing 
process.  
 
 
 
Figure 14 – Transcriptional profile of Hek293 untreated (left) versus treated (right) with IVS8-LNA cells. M – Molecular 
marker pBR322xMspI (New England Biolabs). 
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Discussion  
 
Most population studies revealed that Classical Galactosemia displays a wide 
mutational spectrum, essentially composed by missense mutations ( 70%) [11,14,21]. A 
significant number of them have already been characterized as disease-causing mutations 
by heterologous expression of the recombinant proteins, showing that they affect the enzyme 
structure and/or function [30]. Nevertheless, the number of GALT splicing variations is also 
significant but none of them has already been functionally characterized [16]. On the other 
hand, the study of the Portuguese galactosemic population evidenced the c.820+13a>g 
(IVS8+13a>g) mutation as the second most prevalent, accounting for 12.5% of all mutant 
alleles [19,31,32]. This mutation is classified as benign in the GALT mutation database [16]; 
however, it has been exclusively observed in patients and never in control individuals, which 
strongly suggests its responsibility on the galactosemic phenotype. Accordingly, these data 
were the rationale for the present study. 
The first approach was to evaluate the mutation pathogenicity by in silico analyses. 
Using web-based programs that predict splice site strength and search for ESE and ESS 
motifs, we could determine that the c.820+13a>g mutation activates a cryptic splice donor 
site (Table 2), immediately downstream of the nucleotide variation (c.820+14_15), which also 
creates a strong ESE motif for the binding of the SRSF1 protein. These first results strongly 
suggested c.820+13a>g as a pathogenic mutation. 
In order to elucidate the underlying pathogenic mechanism, we used an in vitro 
minigene approach. After cloning the GALT sequence of interest in an exon-trapping vector 
(Figure 6), we evaluated the splicing mechanism occurring in two types of eukaryotic cells, 
Hek293 and COS-7. The transcriptional profile was always complex, revealing the presence 
of alternative transcripts (Figures 7 and 8). This fact was expected once the conditions are 
dissimilar from the ones in the human cell, where the entire GALT pre-mRNA is spliced. 
However, the most important result was the observation that the minigene construct carrying 
the GALT mutant sequence, encompassing the c.820+13a>g mutation, originated transcripts 
containing the first 13 nucleotides of intron 8 (Figures 7, 8, 9, 11).  
This result showed that the presence of the c.820+13a>g mutation activates the 
downstream cryptic 5’ splice donor site, whose strength completely overlaps those of the 
canonic one. The activation of cryptic splice donor sites is a pathogenic mechanism already 
described in several diseases [33,34,35]. Additionally, this mutation creates a strong ESE 
motif (CCCAGGT) for the binding of the SRSF1 protein. It is known the involvement of this 
and other SR proteins in the recruitment of U1 snRNP and its importance for the early 
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spliceosome assembly [36]. Therefore, we hypothesize that c.820+13a>g mutation induces 
an alternative SRSF1 binding, which may cause a shift in the spliceossomal assembly, 
preventing splicing in the natural 5’GT and leading to the c.820+14_15 usage instead. 
In parallel to the in vitro analyses, we have evaluated the in vivo process. Accordingly, 
we selected a GALT-deficient patient, homozygous for this mutation, from whose 
lymphocytes we prepared total RNA. His transcriptional profile revealed two bands: the larger 
one contained the additional first 13 nucleotides of intron 8, as expected (Figures 12 and 
13.A). The smallest band translated a splicing event leading to the skipping of exon 9 
(Figures 12 and 13.B) and has never been reported before. Nevertheless, this exon skipping 
was surely induced by the weakness of the 3’AG acceptor site in intron 8, already detected 
by the predictive programs used in the in silico analysis.  
It is interesting to note that both transcripts displayed by the patient, containing the 
additional 13 nucleotides, cause a frameshift in the open reading frame and induce a 
premature stop codon. Usually, these transcripts are directed to the nonsense mediated 
decay (NMD) system and are not detected [37,38,39]. Presently, after cloning the mutant 
cDNA on an appropriate expression vector, we are performing the heterologous expression 
of the mutant protein in E.coli cells to evaluate the structure and function of the protein 
potentially produced.  
As previously referred in the Introduction, dietary restriction of galactose, the standard of 
care for Classical Galactosemia treatment, is clearly insufficient and new alternative 
therapeutics are urging. Accordingly, we tried to correct this splicing defect using antisense 
oligonucleotides (AO), the most used approach in these cases [40,41,42]. The rationale for 
its usage relies on the AO hybridization to the mutant region, hindering the assembly of the 
spliceosome. Once the mutation is too close to the canonical 5’GT donor site, the use of 
morpholinos seemed not adequate due to their large volume. The selected alternative was 
the use of locked nucleic acids (LNA), ribose nucleotides which RNA moieties are modified 
with an extra bridge connecting the 2' oxygen and the 4' carbon. However, the cotransfection 
of the eukaryotic cells with the mutant construct and the IVS8-LNA produced no splicing 
correction (Figure 14). The first approach to solve this problem will be the design of new LNA 
sequences, trying to find the effective binding site of the AO in order to block the access of 
the first spliceosomal protein, the U1 snRNP to the cryptic splice site and to force its binding 
to the natural one. 
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Conclusion 
 
The use of web-based programs for in silico prediction of the pathogenic mechanisms 
underlying nucleotide substitutions, as well as the minigene approach to in vitro evaluate the 
results of the splicing events, revealed to be excellent tools for studying nucleotide variations 
potentially affecting the splicing process. Finally, the study of a homozygous patient allowed 
us to validate the in silico and in vitro results and definitively classify c.820+13a>g 
(IVS8+13a>g) as a disease-causing mutation. 
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Supplementary data 
 
 
CACCTTGATGACTTCCTATCCATTCTGTCTTCCTAGGAACGTCTGGTCCTAACCAGTGAGCACTGGTTAGTACTG
GTCCCCTTCTGGGCAACATGGCCCTACCAGACACTGCTGCTGCCCCGTCGGCATGTGCGGCGGCTACCTGAGCTG
ACCCCTGCTGAGCGTGATGGTCAGTCTCCCAGGTAGGATCCTGGGGCTAGGCACTGGATGGAGGTTGCTCCCAGT
AGGGTCAGCATCTGGACCCCAGGCTGAGAGTCAGGCTCTGATTCCAGATCTAGCCTCCATCATGAAGAAGCTCTT
GACCAAGTATGACAACCTCTTTGAGACGTCCTTTCCCTACTCCATGGGCTGGCATGGTGAGGCTTTTCAAGTACC
TATATTTAGCCCCAACACCATTTC 
 
 
Figure S1 – Sequence of the mutant 399bp fragment  of GALT gene including the last portion of intron 7, whole exon 8, intron 8 
and exon 9, and the first portion of intron 9. In red are the exons 8 and 9. The sequences in yellow and green correspond to 
primers 8+9F and 8+9R. In blue is the sequence complementar to IVS8-LNA. The c.820+13a>g mutation is in dark green. 
 
 
 
 
 
